Mirtazapine Reduces Adipocyte Hypertrophy and Increases Glucose Transporter Expression in Obese Mice
Autor: | Wei-Cheng Yang, Geng-Ruei Chang, Chen-Si Lin, Ching-Yang Wu, Ching-Feng Wu, Frank Chiahung Mao, Huei-Jyuan Liao, Hsiao-Pei Tsai, Po-Hsun Hou, Yao-Chi Su |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
medicine.medical_specialty insulin obesity medicine.medical_treatment Mirtazapine Type 2 diabetes White adipose tissue adipocyte Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Adipocyte lcsh:Zoology medicine blood glucose lcsh:QL1-991 mirtazapine lcsh:Veterinary medicine General Veterinary business.industry Insulin Fatty liver Glucose transporter medicine.disease 030104 developmental biology Endocrinology chemistry 030220 oncology & carcinogenesis lcsh:SF600-1100 Animal Science and Zoology Metabolic syndrome business medicine.drug |
Zdroj: | Animals, Vol 10, Iss 1423, p 1423 (2020) Animals : an Open Access Journal from MDPI Animals Volume 10 Issue 8 |
ISSN: | 2076-2615 |
Popis: | Metabolic syndrome is known to engender type 2 diabetes as well as some cardiac, cerebrovascular, and kidney diseases. Mirtazapine&mdash an atypical second-generation antipsychotic drug with less severe side effects than atypical first-generation antipsychotics&mdash may have positive effects on blood glucose levels and obesity. In our executed study, we treated male high-fat diet (HFD)-fed C57BL/6J mice with mirtazapine (10 mg/kg/day mirtazapine) for 4 weeks to understand its antiobesity effects. We noted these mice to exhibit lower insulin levels, daily food efficiency, body weight, serum triglyceride levels, aspartate aminotransferase levels, liver and epididymal fat pad weight, and fatty acid regulation marker expression when compared with their counterparts (i.e., HFD-fed control mice). Furthermore, we determined a considerable drop in fatty liver scores and mean fat cell size in the epididymal white adipose tissue in the treated mice, corresponding to AMP-activated protein kinase expression activation. Notably, the treated mice showed lower glucose tolerance and blood glucose levels, but higher glucose transporter 4 expression. Overall, the aforementioned findings signify that mirtazapine could reduce lipid accumulation and thus prevent HFD-induced increase in body weight. In conclusion, mirtazapine may be useful in body weight control and antihyperglycemia therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |